(Reuters) – Biogen said on Wednesday it had agreed to buy privately held Human Immunology Biosciences for $1.15 billion in upfront and up to $650 million in potential milestone payments.
(Reporting by Manas Mishra in Bengaluru; Editing by Sriraj Kalluvila)
Comments